Download video

Jeffrey Weber, MD, PhD: Predicting Durable Responses to Targeted Therapy

73 views

Targeted Oncology

8 years ago

Jeffrey Weber, MD, PhD: Predicting Durable Responses to Targeted Therapy

Jeffrey Weber, MD, PhD: Predicting Durable Responses to Targeted Therapy

Jeffrey Weber, MD, PhD: Predicting Durable Responses to Targeted Therapy
1:44
Jeffrey Weber, MD, PhD: Predicting Durable Responses to Targeted Therapy
by Targeted Oncology
Jeffrey Weber, MD, PhD: Durability of a Response to Targeted Therapy Combination
1:01
Jeffrey Weber, MD, PhD: Durability of a Response to Targeted Therapy Combination
by Targeted Oncology
Jeffrey Weber, MD, PhD: The Association Between Durable Response and Low Disease Burden
2:20
Jeffrey Weber, MD, PhD: The Association Between Durable Response and Low Disease Burden
by Targeted Oncology
Jeffrey Weber, MD, PhD: The Role of LDH, Age, and Sites of Disease in Durability of Response
0:57
Jeffrey Weber, MD, PhD: The Role of LDH, Age, and Sites of Disease in Durability of Response
by Targeted Oncology
Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments
1:28
Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatments
by Targeted Oncology
Dr. Jeffrey Weber on the Keys to Targeted Treatments
1:23
Dr. Jeffrey Weber on the Keys to Targeted Treatments
by Targeted Oncology
Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker
1:46
Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker
by OBRoncology
Jeffrey Weber, MD, PhD: The Impact of BRAF\/MEK Inhibitors in Melanoma
1:28
Jeffrey Weber, MD, PhD: The Impact of BRAF\/MEK Inhibitors in Melanoma
by Targeted Oncology
Dr. Jeffrey S. Weber on Why the Results of CheckMate-064 Were Surprising
2:10
Dr. Jeffrey S. Weber on Why the Results of CheckMate-064 Were Surprising
by OncLive
Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatment
2:19
Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatment
by Targeted Oncology
Dr. Jeffrey Weber on Potential Breakthrough \\
1:21
Dr. Jeffrey Weber on Potential Breakthrough \\"Cures\\" in Melanoma
by Targeted Oncology
Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor
2:34
Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor
by OBRoncology
Jeffrey Weber, MD, PhD discusses the response rates and PFS for longer OS based on immunotherapies
2:00
Jeffrey Weber, MD, PhD discusses the response rates and PFS for longer OS based on immunotherapies
by OBRoncology
Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma
1:03
Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma
by OncLive
Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results
1:26
Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results
by OBRoncology
Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy
1:54
Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy
by OBRoncology
Jeffrey Weber, MD, PhD: Second-Line Therapy
1:17
Jeffrey Weber, MD, PhD: Second-Line Therapy
by Targeted Oncology
Jeffrey Weber Explains Organ-Specific Side Effects of Checkpoint Inhibitors
1:51
Jeffrey Weber Explains Organ-Specific Side Effects of Checkpoint Inhibitors
by OncLive
Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies
1:23
Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies
by OBRoncology
Dr. Weber on Testing Patients with Melanoma for Gene Mutations
1:39
Dr. Weber on Testing Patients with Melanoma for Gene Mutations
by Targeted Oncology